ATAI Life Sciences (ATAI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ATAI ATAI Life Sciences

Watchlist

1.310
+0.020+1.55%

Close Aug 23 16:00 ET

1.300
-0.010-0.76%

Post 19:56 ET

219.82MMarket Cap-3638P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Atai Life Sciences Chief Scientific Officer Details VLS-01 Trial Success - ICYMI | NASDAQ:ATAI, ETR:9VC
Proactive InvestorsAug 17 04:05 ET
Maxim Group Maintains ATAI Life Sciences(ATAI.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsAug 16 13:31 ET · Ratings
Positive Outlook for ATAI Life Sciences Amidst Upcoming Clinical Trials and Strategic Collaborations
TipRanksAug 16 13:15 ET
CCORF Maintains ATAI Life Sciences(ATAI.US) With Buy Rating, Maintains Target Price $11
Moomoo NewsAug 16 07:31 ET · Ratings
Buy Rating Affirmed for ATAI Life Sciences With Promising Clinical Outlook and Strategic Pipeline Reprioritization
TipRanksAug 16 06:41 ET · Ratings
Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD
Seeking AlphaAug 15 15:02 ET

Comments

Jaguar8

Aug 13 08:23

NEWS

$ATAI Life Sciences (ATAI.US)$
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
atai Life Sciences (NASDAQ: ATAI)announced positive preliminary results from its Phase 1b trial of VLS-01, a proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT). The trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of VLS-01 compared to intravenous DMT in healthy participants.
Key findings include:
D...